Jupiter Life Line Hospitals (JLHL) Q3 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 25/26 earnings summary
9 Jul, 2026Executive summary
Dombivli hospital, a 500-bed facility, was completed ahead of schedule and on budget, with 200 beds operational initially and full operations set for mid-February 2026; OPD services to start in early February 2026.
Pune South project construction has started, Mira Road is under regulatory approval, and Bibwewadi (Pune) is in early construction with minimal CapEx so far.
Existing hospitals show steady operating momentum, with no major operational surprises except for a one-time labor code impact.
Financial highlights
Q3 FY26 total income: INR 366.5 crore, up 9.8% year-over-year; EBITDA: INR 83.4 crore, up 9.2% year-over-year; EBITDA margin: 22.8%.
Q3 PAT: INR 42.5 crore, down 18.7% year-over-year, impacted by a one-time labor code provision of INR 6.4 crore.
9M FY26 total income: INR 1,111.9 crore, up 15.1% year-over-year; EBITDA: INR 254 crore, up 15.2% year-over-year; EBITDA margin: 22.8%.
9M PAT: INR 143.9 crore, down 3.1% year-over-year, also impacted by labor code changes.
Q3 ARPOB: INR 68,000; 9M ARPOB: INR 66,800; 9M ALOS: 3.85 days; 9M occupancy: 61.9% to 67.5%.
Outlook and guidance
Dombivli hospital expected to be EBITDA-negative for the first two years, with break-even anticipated by end of year two.
Consolidated margins will face a drag due to Dombivli's ramp-up; mature hospitals expected to maintain stable margins, while Indore should see incremental margin improvement.
ARPOB for mature assets expected to grow in line with inflation; new hospitals to see faster ARPOB growth in early years.
Total bed capacity expected to increase from 1,048 to approximately 2,500 with upcoming projects.
Latest events from Jupiter Life Line Hospitals
- Q1 FY25 saw strong revenue and EBITDA growth, digital accreditation, and capacity expansion.JLHL
Q1 24/258 Jul 2026 - Strong revenue and profit growth, major hospital expansion, and robust internal funding.JLHL
Q3 24/258 Jul 2026 - Strong revenue and EBITDA growth, stable margins, and major hospital expansions progressing.JLHL
Q2 25/2630 Jun 2026 - Revenue and EBITDA grew over 15%, with major expansion, dividend, and stock split approved.JLHL
Q4 25/2618 May 2026 - Strong revenue and profit growth, with major expansion and capital investment underway.JLHL
Q2 24/253 Feb 2026 - FY25 saw strong growth, a recommended dividend, and major expansion and restructuring.JLHL
Q4 24/2519 Dec 2025 - Q1 FY26 revenue and EBITDA rose, but PAT declined on higher costs; volumes and ARPOB up.JLHL
Q1 25/2619 Dec 2025